NDLI: Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.

Please wait, while we are loading the content...

Year: 2017 Volume: 24

Year: 2016 Volume: 23

Year: 2015 Volume: 22

Year: 2014 Volume: 21

Year: 2013 Volume: 20

Year: 2012 Volume: 19

Year: 2011 Volume: 18

Year: 2011 Volume: 18 Issue: 6

Year: 2011 Volume: 18 Issue: 5

Year: 2011 Volume: 18 Issue: 4

Year: 2011 Volume: 18 Issue: 3

Year: 2011 Volume: 18 Issue: 2

Phosphate enters the syzygy.

World Kidney Day 2011: protect your kidneys, save your heart.

The flux of phosphate: rapid evolution.

Phosphate transporters in renal, gastrointestinal, and other tissues.

The regulation of renal phosphate transport.

Intestinal phosphate transport.

Molecular regulation of phosphate metabolism by fibroblast growth factor-23-klotho system.

The roles of the skeleton and phosphorus in the CKD mineral bone disorder.

Direct effects of phosphate on vascular cell function.

Phosphate and cardiovascular disease.

Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.

Phosphate sensing.

Dynamic imaging of the sodium phosphate cotransporters.

Year: 2011 Volume: 18 Issue: 1

Year: 2010 Volume: 17

Year: 2009 Volume: 16

Year: 2008 Volume: 15

Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Molony, Donald A. Stephens, Brett W.
Description	Country affiliation: United States Author Affiliation: Molony DA ( Division of Renal Diseases and Hypertension, Center for Clinical Research and Evidence-Based Medicine, University of Texas Houston, Medical School, USA. donald.a.molony@uth.tmc.edu)
Abstract	The changes in phosphate (PO(4)) metabolism across the spectrum of chronic kidney disease (CKD) and specific strategies to address these abnormalities by reducing PO(4) loads are discussed in this review. This review also addresses briefly the evidence for specific PO(4) serum targets in CKD and endstage renal disease (ESRD) and the potential for other biomarkers such as fibroblast growth factor-23 (FGF-23) to define disease and monitor the effectiveness of therapy. As renal function declines, single nephron excretion of PO(4) must increase to maintain PO(4) balance. Abnormalities in PO(4) metabolism occur early in CKD. Compensatory changes in renal PO(4) handling are sufficient to maintain a normal serum PO(4) level in early stages of CKD, but in more advanced CKD, these processes no longer suffice and overt hyperphosphatemia develops. The resulting increased PO(4) burden contributes directly to development of secondary hyperparathyroidism. The FGF-23 increases early in CKD, likely in response to abnormal PO(4) metabolism, and mediates processes that help restore serum PO(4) levels to normal in CKD stage 3 and in early stage 4. The increased PO(4) burden and subsequent overt hyperphosphatemia are associated with increased mortality and morbidity. Dietary PO(4) restriction, modification of dialysis prescriptions, and administration of oral PO(4) binders can restore PO(4) balance. As CKD progresses, population-based studies demonstrate that diet alone is typically not able to prevent or treat hyperphosphatemia. Dialysis modalities that are currently used often fail to remove sufficient PO(4) to prevent hyperphosphatemia in patients with an inadequately controlled dietary PO(4) load. This is particularly likely among patients without significant residual renal function. Thus, in the majority of ESRD patients, PO(4) binders remain the mainstay of therapy for hyperphosphatemia. All currently available PO(4) binders can restore serum PO(4) to the required level when administered appropriately and in conjunction with dietary PO(4) restrictions. PO(4) binders differ regarding their potential side-effects and impact on long-term patient-centered outcomes. Which of the PO(4) binders might result in the most favorable survival and cardiovascular morbidity profiles and which remain uncertain, remains a subject of considerable clinical investigation. Compelling observational and more limited randomized controlled trial (RCT) evidence support the view that PO(4) binders might differ in their effects on mortality and/or morbidity. The limited evidence from RCTs is mostly congruent with the findings from large observational studies. In particular, evidences from both epidemiologic and RCT support the view that excess calcium administration may independently increase the risk of cardiovascular disease in individuals with normal renal function and in patients with CKD and ESRD. Additional RCT evidence might help determine the degree at which any increased risk from oral calcium exposure can be mitigated with the use of noncalcium-based PO(4) binders. Judicious control of PO(4) early in CKD, possibly monitored by measures of FGF-23, could potentially reduce the risk of development of renal secondary hyperparathyroidism and all of the adverse clinical consequences of poorly controlled CKD-mineral and bone disorder. The mainstays of therapy are likely to include a balance of dietary restriction and PO(4) binders to reduce PO(4) input, and in ESRD patients, dialysis modalities to augment PO(4) output.
File Format	HTM / HTML
ISSN	15485595
e-ISSN	15485609
Journal	Advances in Chronic Kidney Disease
Issue Number	2
Volume Number	18
Language	English
Publisher	Elsevier
Publisher Date	2011-03-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Nephrology Phosphates Metabolism Renal Insufficiency, Chronic Therapy Bone Diseases, Metabolic Renal Osteodystrophy Fibroblast Growth Factors Hyperphosphatemia Kidney Failure, Chronic Phosphate-binding Proteins Therapeutic Use Phosphorus, Dietary Renal Dialysis Syndrome
Content Type	Text
Resource Type	Article
Subject	Nephrology

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in